iECURE
Mike Burnham has a diverse work experience. Mike is currently working as the Senior Director Manufacturing Sciences & Technology Lead at iECURE, inc. Mike previously held the position of Senior Director, Vector Development at Resilience from 2022 to 2023. Prior to that, they worked at Tmunity Therapeutics Incorporated as the Senior Director, Vector Development from 2020 to 2022 and as the Director, Vector Development from 2018 to 2020. Before joining Tmunity, they served as a Senior Principal Scientist at WuXi Advanced Therapies from 2016 to 2018. Mike began their career at WuXi AppTec, Inc. as the Director, Purification & Process Development from 2012 to 2016.
Mike Burnham earned a Master's degree in Biology/Biological Sciences from Rutgers University between 1996 and 2000. Prior to that, they obtained a BA in Biology from the University of Delaware from 1988 to 1992. Their high school education was completed at Cape Henlopen High School, although the specific years are not provided. Additionally, they have a pending certification in Statistics Foundations 1: The Basics from LinkedIn, which is expected to be obtained in 2023.
iECURE
1 followers
iECURE is a gene editing company focused on developing therapies that utilize mutation-agnostic in vivo gene insertion, or knock-in, editing for the treatment of liver disorders with significant unmet need. We believe our approach has the potential to replace and restore the function of a dysfunctional gene by knocking-in a healthy copy, regardless of mutation, to offer durable gene expression and long-term, potentially curative, therapeutic benefit. Our management team has extensive experience in executing global orphan drug and gene therapy clinical trials and successfully commercializing multiple products. We intend to leverage our team’s core strength in research and development strategy to identify what we believe to be the most suitable target and modality for our product candidates to address particular liver diseases. We are collaborating with the University of Pennsylvania’s Gene Therapy Program, or GTP, led by James M. Wilson, M.D., Ph.D., to utilize GTP’s world-class translational expertise and infrastructure, which has helped generate our initial pipeline of potential product candidates.